Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted stearoyl-coenzyme A desaturase-1 modulator oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH) for various populations. Co. is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide. Co.'s product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule that Co. is developing for oral treatment for NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. We show 9 historical shares outstanding datapoints in our coverage of GLMD's shares outstanding history.
Understanding the changing numbers of GLMD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like GLMD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching GLMD by allowing them to research GLMD shares outstanding history
as well as any other stock in our coverage universe. |
Free GLMD Email Alerts:
Video: Shares Outstanding Importance
